StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Nektar Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$139.08M. For fiscal 2025 it was -$139.08M. The highest annual figure on record is $696.73M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$139.08M–
FY2024Dec 31, 2024-$100.81M–
FY2023Dec 31, 2023-$256.68M–
FY2022Dec 31, 2022-$363.97M–
FY2021Dec 31, 2021-$433.10M–
FY2020Dec 31, 2020-$412.61M–
FY2019Dec 31, 2019-$429.04M-161.6%
FY2018Dec 31, 2018$696.73M–
FY2017Dec 31, 2017-$47.04M–
FY2016Dec 31, 2016-$99.66M–
FY2015Dec 31, 2015-$17.97M–
FY2014Dec 31, 2014-$3.56M–
FY2013Dec 31, 2013-$105.86M–
FY2012Dec 31, 2012-$126.69M–
FY2011Dec 31, 2011-$108.99M–
FY2010Dec 31, 2010-$11.70M–
FY2009Dec 31, 2009-$80.25M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$27.48M-287.2%
Q3 FY2025Sep 30, 2025-$31.48M–
Q2 FY2025Jun 30, 2025-$36.02M–
Q1 FY2025Mar 31, 2025-$44.11M–
Q4 FY2024Dec 31, 2024$14.68M–
Q3 FY2024Sep 30, 2024-$33.35M–
Q2 FY2024Jun 30, 2024-$48.32M–
Q1 FY2024Mar 31, 2024-$33.82M–
Q4 FY2023Dec 31, 2023-$32.67M–
Q3 FY2023Sep 30, 2023-$43.17M–
Q2 FY2023Jun 30, 2023-$48.43M–
Q1 FY2023Mar 31, 2023-$132.41M–
Q4 FY2022Dec 31, 2022-$50.12M–
Q3 FY2022Sep 30, 2022-$51.62M–
Q2 FY2022Jun 30, 2022-$149.40M–
Q1 FY2022Mar 31, 2022-$112.83M–
Q4 FY2021Dec 31, 2021-$110.62M–
Q3 FY2021Sep 30, 2021-$109.98M–
Q2 FY2021Jun 30, 2021-$106.66M–
Q1 FY2021Mar 31, 2021-$105.85M–
Q4 FY2020Dec 31, 2020-$109.16M–
Q3 FY2020Sep 30, 2020-$99.81M–
Q2 FY2020Jun 30, 2020-$74.52M–
Q1 FY2020Mar 31, 2020-$129.13M–
Q4 FY2019Dec 31, 2019-$108.22M–
Q3 FY2019Sep 30, 2019-$95.29M–
Q2 FY2019Jun 30, 2019-$107.92M-111.1%
Q1 FY2019Mar 31, 2019-$117.61M–
Q4 FY2018Dec 31, 2018-$99.29M–
Q3 FY2018Sep 30, 2018-$95.95M-230.9%
Q2 FY2018Jun 30, 2018$976.17M–
Q1 FY2018Mar 31, 2018-$84.20M–
Q4 FY2017Dec 31, 2017-$23.52M–
Q3 FY2017Sep 30, 2017$73.28M–
Q2 FY2017Jun 30, 2017-$46.40M–
Q1 FY2017Mar 31, 2017-$50.40M–
Q4 FY2016Dec 31, 2016-$30.45M–
Q3 FY2016Sep 30, 2016-$29.03M–
Q2 FY2016Jun 30, 2016-$34.41M–

More Nektar Therapeutics figures

See a number that looks wrong?